SIDC actively participates in human clinical research and human clinical trials. In our research efforts, we focus on HIV infection and prevention, sexually transmitted disease treatment and diagnosis, vaccination for prevention of illness, and diagnosis and treatment of infectious diseases.
Active Clinical Research
Phase 2 Study of VE303 for Prevention of Recurrent Clostridium Difficile Infection (CONSORTIUM)
This study is evaluating an engineered probiotic-like novel therapeutic formulation of live bacteria to prevent recurrent C diff infection in addition to Standard-of-Care antibiotic treatment. The Consortium Study is actively enrolling new subjects; Call us if you are interested in learning more.
Link to ClinicTrials.gov. Sponsored by Vedanta Biosciences, Inc.
Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection (DISCOVER)
This study is evaluating one of two medications to prevent HVI-infection in high-risk person. This is a registrational trial that resulted in the FDA approval of Descovy-PrEP in addition to the prior Standard-of-Care Truvada-PrEP.
The Discover Trial is no longer enrolling subjects. Participants completed blinded study medication in 2019 and participants will complete the open-label portion of the study in the fall of 2020. Data analysis will continue until 2022.
Link to ClinicTrials.gov. Sponsored by Gilead Sciences, Inc.